REFERENCE:-

1. Aaboe K, Knop FK, Vilsboll T, et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes ObesMetab. 2010 Apr;12(4):323–33. [PubMed]

2. Adriaanse, M. C., Dekker, J. M., Heine, R. J., Snoek, F. J., Beekman, A. J., Stehouwer, C. D., et al. (2008). Symptoms of depression in people with impaired glucose metabolism or type 2 diabetes mellitus: The Hoorn study. Diabetic Medicine, 25, 843–849.

3. Aikens, J. E., &Piette, J. D. (2009). Diabetic patients' medication underuse, illness outcomes, and beliefs about antihyperglycemics and antihypertensive treatments. Diabetes Care, 32, 19–24.

4. Ali, S., Stone, M. A., Peters, J. L., Davies, M. J., &Khunti, K. (2006). The prevalence of co-morbid depression in adults with type 2 diabetes: A systematic review and meta-analysis. Diabetic Medicine, 23, 1165–1173.

5. Anderson, R. J., Freedland, K. E., Clouse, R. E., &Lustman, P. J. (2001). The prevalence of comorbid depres- sion in adults with diabetes: A meta-analysis. Diabetes Care, 24, 1069–1078

6. Anderson, R. M. (1995A). Patient empowerment and the traditional medical model. A case of irreconcilable differences? Diabetes Care, 18, 412–415.

7. Arjona Ferreira JC, Marre M, Barzilai N, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care. 2013 May;36(5):1067–73.[PMC free article] [PubMed]

8. Anderson, R. J., K. E. Freedland, R. E. Clouse and P. J. Lustman (2001). The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 24(6): 1069-1078 .

9. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003 Jan;17(1):7–12. 2003. [PubMed]

10. Beck, A. T. (2016). Cognitive Therapy: Nature and Relation to Behavior Therapy – Republished Article. BehavTher 47(6): 776-784. PubMed abstract

11. Butler, A. C., J. E. Chapman, E. M. Forman and A. T. Beck (2006). The empirical status of cognitive-behavioral therapy: a review of meta-analyses. ClinPsychol Rev 26(1): 17-31. PubMed abstract

12. Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation.

13. Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., &Erbaugh, J. (1961). An inventory for measuring depres- sion. Archives of General Psychiatry, 4, 561–571.

14. Centers for Disease Control and Prevention. (2008). National diabetes fact sheet: General information and national estimates on diabetes in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.

15. Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., et al. (2000). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adher- ence instruments. AIDS Care, 12, 255–266.

16. Chien HH, Chang CT, Chu NF, et al. Effect of glyburide-metformin combination tablet in patients with type 2 diabetes. J Chin Med Assoc. 2007 Nov;70(11):473–80. 2007. [PubMed]

17. Comaschi M, Demicheli A, Di Pietro C, et al. Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes. Diabetes TechnolTher. 2007 Aug;9(4):387–98. 2007. [PubMed]

18. de Groot, M., Anderson, R., Freedland, K. E., Clouse, R. E., &Lustman, P. J. (2001). Association of depression and diabetes complications: A meta-analysis. Psychosomatic Medicine, 63, 619–630.

19. DiMatteo, M. R. (2004). Variations in patients' adherence to medical recommendations: a quantitative re- view of 50 years of research. Medical Care, 42, 200–209.

20. Gholap N et al. Type 2 diabetes and cardiovascular disease in South Asians. Prim. Care Diabetes, 2011, 5:45–56.

21. Halford, J. B., T. (2009). Cognitive–behavioural therapy as an adjunctive treatment in chronic physical illness. Advances in Psychiatric Treatment 15(4): 306-317

22. IDF Atlas 2012. Available at http://www.idf.org/sites/default/files/5E_IDFAtlasPoster_2012_EN.pdf.

23. Joshi SR, Parikh RM. India - diabetes capital of the world: now heading towards hypertension. J Assoc Physicians India. 2007;55:323–4. [PubMed]

24. Kumar A, Goel MK, Jain RB, Khanna P, Chaudhary V. India towards diabetes control: Key issues. Australas Med J. 2013;6(10):524–31. [PMC free article] [PubMed]

25. Patterson CC et al. 2012. Trends in childhood type 1 diabetes incidence in Europe during 1989- 2008: evidence of non-uniformity over time in rates of increase. Diabetologia, 2012. 55(8):2142- 7.

26. Rastogi A, Bhadada SK, Saikia UN, Bhansali A. Recurrent diabetic myonecrosis: a rare complication of a common disease. Indian J Med Sci. 2011;65(7):311–4. [PubMed]

27. Schernthaner G, Duran-Garcia S, Hanefeld M, et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes ObesMetab. 2015 Jul;17(7):630–[PubMed]

28. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes research and clinical practice, 87: 2010 4-14

29. Sukala WR, Page RA, Rowlands DS, Lys I, Krebs JD, Leikis MJ, Cheema BS. Exercise intervention in New Zealand Polynesian peoples with type 2 diabetes: Cultural considerations and clinical trial recommendations. Australas Med J. 2012;5(8):429–35. [PMC free article] [PubMed]

30. Taylor, R. (2006). Cognitive Behavioral Therapy for Chronic Illness and Disability, Springer US. PubMed abstract

31. World Health Organization, Global Burden of Disease Database 2008. Available at http://www.who.int/healthinfo/global_burden_disease/projections/en/index.html.

32. Wild S et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004, 27 (5) 1047–1053

33. White, C. A. (2001). Cognitive behavioral principles in managing chronic disease. West J Med 175(5): 338-342.

34. Wellen, K. E. and G. S. Hotamisligil (2005). Inflammation, stress, and diabetes. J Clin Invest 115(5): 1111-1119. PubMed abstract.

35. Wallerstein, N., & Duran, B. (2010). Community-based participatory research contributions to intervention research: The intersection of science and practice to improve health equity. American Journal of Public Health, 100(Suppl. 1), S40–S46. doi:10.2105/AJPH.2009 .184036.

36. Wells-Federman, C., Arnstein, P., & Caudill, M. (2002). Nurse-led pain management program: Effect on self-efficacy, pain intensity, pain-related disability, and depressive symptoms in chronic pain patients. Pain Management Nursing, 3(4), 131–140. doi:10.1053/jpmn.2002 .127178.

37. Williams, A. C., Eccleston, C., & Morley, S. (2012). Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database of Systematic Reviews, 2012(11), Article No. CD007407. doi:10.1002/14651858.CD007407.pub3

38. Williams, D. A., Kuper, D., Segar, M., Mohan, N., Sheth, M., &Clauw, D. J. (2010). Internet-enhanced management of fibromyalgia: A ran- domized controlled trial. Pain, 151(3), 694–702. doi:10.1016/j.pain .2010.08.034.

39. Yates, S. L., Morley, S., Eccleston, C., & Williams, A. C. (2005). A scale for rating the quality of psychological trials for pain. Pain, 117(3), 314–325. doi:10.1016/j.pain.2005.06.018